Literature DB >> 22977056

Nitrofurantoin-induced microangiopathic haemolytic anaemia and thrombocytopaenia in a patient with systemic lupus erythematosus.

Linnette López-López1, Noridza Rivera-Rodríguez, Luis M Vilá.   

Abstract

Patients with systemic lupus erythematosus (SLE) may develop thrombotic thrombocytopaenic purpura (TTP) or TTP-like illness manifested by microangiopathic haemolytic anaemia (MAHA) and thrombocytopaenia. The distinction between active SLE and TTP is difficult because these entities share similar clinical features. Drug-induced TTP caused by an immune-mediated reaction have been documented for several drugs. Herein, we report a middle-aged Hispanic woman with long-standing SLE, who developed a TTP-like illness characterised by MAHA and thrombocytopaenia after exposure to nitrofurantoin. The patient responded well to plasmapheresis and immunosuppressive therapy and has remained clinically stable after 18 months of follow-up. To our knowledge, this is the first case that reports the association between nitrofurantoin and a TTP-like presentation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22977056      PMCID: PMC4543959          DOI: 10.1136/bcr-2012-006507

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  23 in total

1.  Frequency of microangiopathic hemolytic anemia in patients with systemic lupus erythematosus exacerbation: Distinction from thrombotic thrombocytopenic purpura, prognosis, and outcome.

Authors:  Sylvia Dold; Ranju Singh; Haroon Sarwar; Yamini Menon; Liliana Candia; Luis R Espinoza
Journal:  Arthritis Rheum       Date:  2005-12-15

2.  Nitrofurantoin-induced antinuclear antibodies and panniculitis.

Authors:  R G Sanford; P M Olmstead
Journal:  Arthritis Rheum       Date:  1987-09

3.  Thrombotic microangiopathic hemolytic anemia with reduction of ADAMTS13 activity: initial manifestation of childhood-onset systemic lupus erythematosus.

Authors:  Eyal Muscal; Rachel M Edwards; Debra L Kearney; John M Hicks; Barry L Myones; Jun Teruya
Journal:  Am J Clin Pathol       Date:  2011-03       Impact factor: 2.493

Review 4.  Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13.

Authors:  Frederick Lansigan; Iris Isufi; Clement E Tagoe
Journal:  Rheumatology (Oxford)       Date:  2010-12-11       Impact factor: 7.580

5.  Antibiotic allergy in systemic lupus erythematosus: a case-control study.

Authors:  M Petri; J Allbritton
Journal:  J Rheumatol       Date:  1992-02       Impact factor: 4.666

6.  Frequency of adverse drug reactions in patients with systemic lupus erythematosus.

Authors:  Janet Pope; Dana Jerome; Deborah Fenlon; Adriana Krizova; Janine Ouimet
Journal:  J Rheumatol       Date:  2003-03       Impact factor: 4.666

7.  Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study.

Authors:  S K Kwok; J H Ju; C S Cho; H Y Kim; S H Park
Journal:  Lupus       Date:  2009-01       Impact factor: 2.911

8.  Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases.

Authors:  Tomomi Matsuyama; Masataka Kuwana; Masanori Matsumoto; Ayami Isonishi; Shigeko Inokuma; Yoshihiro Fujimura
Journal:  Thromb Haemost       Date:  2009-08       Impact factor: 5.249

9.  Systemic lupus erythematosus presenting as thrombotic thrombocytopenia purpura: how close is close enough?

Authors:  Cesar A Perez; Nabil Abdo; Anuj Shrestha; Edgardo S Santos
Journal:  Case Rep Med       Date:  2011-05-10

Review 10.  Drug-induced autoimmune-like hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-02-16       Impact factor: 3.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.